Population-based model to estimate potential impact of glucagon-like peptide-1 receptor agonists on cancer incidence in the US

The current overweight and obesity prevalence in the US is 36.2% and 39.5% among male individuals and 28.8% and 41.4% among female individuals, respectively. A modeling study projected that, in 2030, 18.0% of all obesity-related cancers (ORCs) among women and 14.3% of all ORCs among men would be attributable to high BMI, with increase of 13 ORCs by 26.6% between 2025 and 2050. A glucagon-like peptide-1 receptor agonist-related 10% weight reduction could lead to a total reduction of 1,222,584 ORC cases among men and women combined by 2050. The largest prevention potential was projected for breast and endometrial cancers among female individuals and for kidney and liver cancers among both sexes.